Skip to content

13F-HR filed by GREAT POINT PARTNERS LLC

GREAT POINT PARTNERS LLC filed this 13F-HR for the quarter ended 2025-03-31, filed 2025-05-15, with 32 holding rows worth $188,796,269.

Accession
0001172661-25-002331
Filed
2025-05-15
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q1 2025

A holdings report, 32 entries on the cover page, a total value of $188,796,269 stated on the cover page (in dollars after the unit check, H1), rows summing to $188,796,269 with VALUE read as dollars as filed, 13F file number 028-11743. The quarter's positions are built on this report. The resolved quarter.

Other managers

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
CYTOKINETICS INC23282W605COM NEW370,000$14,870,300dollars as filed
KALVISTA PHARMACEUTICALS INC483497103COM1,014,367$11,705,795dollars as filed
EVOLUS INC30052C107COM944,743$11,365,258dollars as filed
ABIVAX SA-00370M103SPONSORED ADS1,638,111$10,238,194dollars as filed
VIRIDIAN THERAPEUTICS INC92790C104COM750,000$10,110,000dollars as filed
MERUS N VN5749R100COM237,156$9,981,896dollars as filed
AKEBIA THERAPEUTICS INC00972D105COMMON STOCK4,973,840$9,549,773dollars as filed
XENON PHARMACEUTICALS INC COM98420N105Stock245,272$8,228,876dollars as filed
ASCENDIS PHARMA A/S DKK 1.0 AD04351P101SPONSORED ADR50,000$7,793,000dollars as filed
DYNAVAX TECHNOLOGIES CORP268158201COM NEW595,879$7,728,551dollars as filed
IONIS PHARMACEUTICALS INC COM462222100Stock250,000$7,542,500dollars as filed
AMYLYX PHARMACEUTICALS INC03237H101COM1,811,996$6,414,466dollars as filed
IMMUNOVANT INC45258J102COM375,000$6,408,750dollars as filed
UNICYCIVE THERAPEUTICS INC90466Y103CMN10,980,000$6,312,402dollars as filed
NEUROGENE INC64135M105COMMON STOCK470,964$5,514,988dollars as filed
DIANTHUS THERAPEUTICS INC252828108COM275,000$4,988,500dollars as filed
SUMMIT THERAPEUTICS INC86627T108COM250,000$4,822,500dollars as filedput
LEGEND BIOTECH CORP52490G102SPONSORED ADS138,240$4,690,483dollars as filed
VAXCYTE INC COM92243G108Stock115,517$4,361,922dollars as filed
AUTOLUS THERAPEUTICS PLC SPON05280R100COM2,728,910$4,229,811dollars as filed
HELIX ACQUISITION CORP IIG4444H101CL A ORD SHS373,833$4,224,313dollars as filed
ZURA BIO LTDG9TY5A101COMMON STOCK3,170,194$4,089,550dollars as filed
BEAM THERAPEUTICS INC07373V105COM175,562$3,428,726dollars as filed
ARCELLX INC COMMON STOCK03940C100Stock45,000$2,952,000dollars as filed
MEREO BIOPHARMA GROUP PLC589492107CMN1,275,000$2,868,750dollars as filed
CONTEXT THERAPEUTICS INC21077P108COM4,683,711$2,866,431dollars as filed
REZOLUTE INC76200L309COMMON STOCK833,042$2,415,822dollars as filed
CENTESSA PHARMACEUTICALS PLC152309100SPONSORED ADS149,702$2,152,715dollars as filed
VOYAGER THERAPEUTICS INC92915B106COMMON STOCK626,275$2,116,810dollars as filed
PROMIS NEUROSCIENCES INC74346M406COM NEW2,645,128$1,839,687dollars as filed
UPSTREAM BIO INC91678A107COMMON STOCK300,000$1,836,000dollars as filed
PLIANT THERAPEUTICS INC729139105COM850,000$1,147,500dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001172661-25-002331this filing2025-05-15acceptance time not in the bulk data set